Fig. 5From: Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetesFive weeks of empagliflozin treatment reduces the profibrotic protein expression levels of a, b ENaC and c SGK1. AGSI average grey scale intensities, AU arbitrary units *P < 0.05 vs CkC; †P < 0.05 vs DbC. Scale bars 50 μmBack to article page